Keno Gutierrez joins Angelini Ventures as Partner, Biotech
Keno brings more than 25 years across biotech investing, company building and operations, most recently as General Partner at BGV. He will work with Regina Hodits, Paolo Di Giorgio and the investment team to lead our biotech strategy.
Angelini Ventures is pleased to welcome Keno Gutierrez, PhD, MBA, as Partner, Biotech. As we expand our investment and company creation efforts, Keno strengthens our biotech leadership. He will partner with Regina Hodits, Paolo Di Giorgio and our investment team to lead and execute an ambitious biotech investment strategy.
Keno brings more than 25 years of experience across investing, entrepreneurship, banking, consulting and R&D.
Most recently he was General Partner at BGV (BioGeneration Ventures), where he led investments including RougeTx, Brenig Therapeutics and FundaMental Pharma. He also founded Brandaris Therapeutics, which he led as CEO and chaired. Earlier, he was VP & Managing Director at M Ventures (Merck KGaA) and held investment roles at Omega Funds.
His career also includes healthcare investment banking at Piper Sandler, management consulting at IQVIA and medical research at the UK Medical Research Council. Keno is a Fellow of the Royal Society of Medicine, holds a PhD in Genetics from University College London and an MBA from INSEAD, and is a named inventor on a neuroscience patent. His research on lipid metabolism was published in Nature.
Welcome to the team, Keno.